Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Phase 4 Study to Investigate the Seropersistence of Tick-borne Encephalitis (TBE) Virus Antibodies From 7 to 10 Years After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults

NCT01582698 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01582698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01582698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Phase 4 Study to Investigate the Seropersistence of Tick-borne Encephalitis (TBE) Virus Antibodies From 7 to 10 Years After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2012
Completion date
June 30, 2015
Enrollment
243 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

tick-borne encephalitis (tbe)